GlassScriptPhysician profile
Eldar Kurtovic
NPI 1427579663
$5,557.63
in general payments reported to CMS, 2019-2025
20 companies · $42.31 in 2025
The $42.31 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $361 · 2020: $14.57 · 2021: $490 · 2022: $3,995 · 2023: $511 · 2024: $144 · 2025: $42.31.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $697.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $697.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,982.72 | 2022-2023 | Cardiomems, Accent |
| Boston Scientific Corporation | $546.55 | 2019-2023 | Eluvia |
| Novartis Pharmaceuticals Corporation | $388.61 | 2019-2025 | |
| Amgen INC. | $290.96 | 2022-2025 | Repatha, Repatha |
| Shockwave Medical, INC | $221.23 | 2022 | |
| Medtronic, INC. | $217.23 | 2021-2023 | Micra |
| Janssen Pharmaceuticals, INC | $175.53 | 2019-2023 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $161.99 | 2021-2023 | Farxiga |
| Teva Pharmaceuticals USA, INC. | $110.42 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $88.41 | 2022-2023 | |
| Actelion Pharmaceuticals US, INC. | $58.48 | 2023 | Uptravi, Opsumit |
| Kiniksa Pharmaceuticals, LTD. | $53.55 | 2022 | |
| Pfizer INC. | $52.17 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.59 | 2022-2023 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $48.68 | 2020-2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Atricure, INC. | $48.00 | 2023 | |
| Scpharmaceuticals INC. | $19.42 | 2024 | |
| Phadia US INC. | $16.54 | 2019 | |
| Novo Nordisk INC | $13.87 | 2019 | |
| Mylan Specialty L.P. | $13.68 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eldar Kurtovic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.